TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

a gene therapy for treatment of Telomere Biology Disorders (TBDs). EXG-34217 is currently being studied in an ongoing Phase 1/2 trial (NCT04211714) for the treatment of patients with TBDs with bone ...

Researchers from the Tata Memorial Centre (TMC), Mumbai, and the National Institute of Biomedical Genomics (NIBMG) in West Bengal on Wednesday claimed to have found key genomic factors that contribute ...

Tech entrepreneur Bryan Johnson has made headlines for his ambitious anti-ageing experiments. In a recent appearance on Realign podcast, he claimed that one can successfully reverse the biological age ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.

A new study suggests that people with shorter protective caps at the ends of their chromosomes, called telomeres, may have a higher risk of developing age-related brain diseases such as stroke ...

Ozone therapy is a controversial alternative medicine practice that involves using ozone gas to fight disease. Currently, there is not enough evidence to conclude it is effective or safe for ...

Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical ...

“This is the first mouse model with truly humanized telomeres because telomerase isn’t expressed in adult tissues in this model,” said Jiyue Zhu, PhD, professor, college of pharmacy and phar ...

This lag in therapeutic response will permit continued tumor cell growth in the presence of therapy for a period of time depending on the telomere length in the tumor cells at the time that ...